Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF
Description
About Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF
The Human Lymphokine-activated killer T-cell-originated protein kinase Peptide (IEDB: 418578) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Lymphokine-activated killer T-cell-originated protein kinase Peptide, H-SYQKVIELF-OH (Uniprot: Q96KB5 aa: 289-297) from JPT is produced under strict quality control and quality management.
Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF - Specifications
- Peptide sequence: H-SYQKVIELF-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF
References:
Read References with JPT’s Antigen Peptides
Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF has been described in:
Improved Survival of a HER2-Positive Metastatic Breast Cancer Patient Following a Personalized Peptide Immunization., Vaccines (Basel), 2023 (PMID: 37376412)
A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes., J Immunol Res, 2014 (PMID: 25802875)
Documentation
Documentation for Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF
Properties
Properties of Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Lymphokine-activated killer T-cell-originated protein kinase |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Lymphokine-activated killer T-cell-originated protein kinase 289-297, SYQKVIELF
Information | Values |
---|---|
Sequence: | H-SYQKVIELF-OH |
Specifications: | 9mer peptide as TFA salt |